Did you know? You can suggest edits to improve this peptide information.
Overview
What is Semaglutide?
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic injectable or Rybelsus oral) and chronic weight management (as Wegovy injectable or oral). In December 2025, oral Wegovy became the first oral GLP-1 approved for weight management, offering a 25mg daily tablet option alongside the established injectable. With over 17,000 participants in clinical trials, semaglutide demonstrates significant weight loss potential (average 15-20% body weight reduction) through appetite suppression, slowed gastric emptying, and enhanced glucose control.
Key Benefits
FDA-approved treatment with established efficacy for weight loss (15-20% average) and diabetes management. Convenient once-weekly dosing with proven cardiovascular benefits and comprehensive safety data from extensive clinical trials.
Mechanism of Action
Subcutaneous semaglutide mimics native GLP-1, binding to GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic pathways. The 7-day half-life allows weekly dosing.
Molecular Information
Weight
4,113.64 Da
Length
31 amino acids
Type
GLP-1 receptor agonist
Amino Acid Sequence:
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
* Acylated with C18 fatty diacid via γ-Glu spacer for extended half-life
Pharmacokinetics
Research Indications
Clinically Significant Weight Reduction
FDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials
Appetite and Craving Control
Reduces hunger and food cravings through central nervous system GLP-1 receptor activation
Sustained Weight Maintenance
Long-term studies show maintained weight loss with continued treatment over 2+ years
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Inject on the same day each week at any time. If you miss a dose and it's within 5 days, take it as soon as remembered. If more than 5 days, skip and resume regular schedule.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
If using pre-filled pen, attach new needle and prime according to instructions
If using vial, draw prescribed dose with appropriate syringe
Clean injection site with alcohol swab and let dry
Inject subcutaneously at 90-degree angle (45-degree if lean)
Hold for 6 seconds after injection to ensure full dose delivery
Dispose of needle safely and rotate injection sites weekly
Quality Indicators
FDA-approved branded products
Use only Ozempic (diabetes) or Wegovy (weight loss) from licensed pharmacies. Oral Wegovy tablets also available for weight management
Proper storage verification
Check that medication was properly refrigerated and not expired
Clear solution in pen/vial
Solution should be clear and colorless to slightly yellow
Compounded versions
FDA warns about untested compounded semaglutide - use only approved products
Cloudy or discolored solution
Do not use if solution is cloudy, has particles, or unusual color
Non-pharmacy sources
Avoid online sources not verified as licensed pharmacies
What to Expect
- Week 1-4: Mild appetite reduction, possible nausea during initial dose
- Month 2-3: Noticeable weight loss (5-10% typical), improved satiety
- Month 4-6: Continued weight loss (10-15% common), stable glucose levels
- Month 6+: Weight loss plateau possible, focus on maintenance
- Diabetes benefits: Blood sugar improvements within 1-2 weeks
- Long-term: Sustained benefits with continued use
Side Effects & Safety
- FDA-approved medication with extensive safety data from trials of 17,000+ participants
- Start low and titrate slowly to minimize GI side effects
- Most common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, belching, gas, heartburn, and upset stomach
- Hair loss and changes in skin sensations have been reported
- Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- May cause thyroid tumors including cancer — tell your provider about neck lumps, hoarseness, trouble swallowing, or shortness of breath
- May cause gallbladder problems including gallstones — some may require surgery
- Can increase heart rate at rest — tell your provider if you feel your heart racing or pounding for several minutes
- Increased risk of low blood sugar (hypoglycemia) when combined with insulin or sulfonylureas
- Dehydration from GI side effects may lead to kidney problems — stay well hydrated
- Tell all healthcare providers you take Wegovy before any surgery or procedure using anesthesia due to aspiration risk
- Stop use 2 months before a planned pregnancy — may harm an unborn baby
- Not recommended during pregnancy or breastfeeding
References
OASIS 4 Oral Semaglutide for Weight Management (2025)
Pivotal Phase III trial supporting FDA approval of oral Wegovy. Adults with obesity or overweight (with at least one weight-related condition) lost on average ~14% of starting body weight (~33 lb from 235 lb) vs 2.4% (~6 lb) with placebo, alongside reduced-calorie diet and increased physical activity. 76% achieved ≥5% weight loss (vs 31% placebo), 60% achieved ≥10% (vs 14%), 47% achieved ≥15% (vs 6%), and 28% achieved ≥20% (vs 3%). Adults with type 2 diabetes were excluded. 18% of Wegovy pill participants discontinued vs 26% on placebo.
SELECT Cardiovascular Outcomes (2023)
Major cardiovascular outcomes trial demonstrating 20% reduction in major adverse cardiovascular events in overweight/obese adults with established CVD.
STEP 5 Two-Year Maintenance (2022)
Two-year study confirming sustained weight loss (15.2% at week 104) with continued treatment, demonstrating long-term efficacy.
Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia